Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Check the time stamp on this data. Updated AI-Generated Signals for Amphastar Pharmaceuticals Inc. (AMPH) available here: ...

Morgan Stanley upgraded Palantir (PLTR) to Equal Weight from Underweight with a price target of $95, up from $60, following ...